fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Triamcinolone acetonide

Form:

10 of 10 products shown

5 general benefit · 5 not a benefit

Triaderm · DIN 00716960 · 0.1% · Cr

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Triaderm · DIN 00716960 Manufacturer: Taro Pharmaceuticals Inc.; listing date 1996-10-01 Health Canada: Marketed since 1979-12-31 · brand TRIADERM CRM 0.1% · ATC D07AB09 TRIAMCINOLONE · form Cream · route Topical · ingredients TRIAMCINOLONE ACETONIDE 0.1 % · company Taro pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Triaderm: Formulary list price $0.05 per unit (the source does not state the unit; exact figure $0.0533). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00716960)

Source record
DIN 00716960: Triaderm Raw flags: sec3=Y Item: 840600029; group id 850; item number 2067; lccId None; manufacturer id TAR Source form: Cr; strength: 0.1% Recorded listing: General benefit Source prices (unrounded): $0.0533; ministry $0.0533 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00716960 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8573
Interchangeable products
Aristocort R · DIN 02194058 · not recorded Kenalog · DIN 00029114 · not recorded
Shortage status: resolved shortage (ended December 22, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00716960
Shortage record checked October 6, 2026

Aristocort R · DIN 02194031 · 0.1% · Oint

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Aristocort R · DIN 02194031 Manufacturer: Valeo Pharma Inc.; listing date 1998-03-17 Health Canada: Marketed since 2020-11-24 · brand ARISTOCORT R · ATC D07AB09 TRIAMCINOLONE · form Ointment · route Topical · ingredients TRIAMCINOLONE ACETONIDE 0.1 %/W/W · company Bausch health, canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Aristocort R: Formulary list price $0.19 per unit (the source does not state the unit; exact figure $0.1856). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02194031)

Source record
DIN 02194031: Aristocort R Raw flags: sec3=Y Item: 840600030; group id 850; item number 2068; lccId None; manufacturer id VAE Source form: Oint; strength: 0.1% Recorded listing: General benefit Source prices (unrounded): $0.1856; ministry $0.1856 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02194031 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=35783
Interchangeable products
Kenalog · DIN 01999796 · not recorded
Shortage status: resolved shortage (ended June 14, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02194031
Shortage record checked October 6, 2026

Kenalog-10 · DIN 01999761 · 50 mg/5 mL · injection suspension-5mL Pk

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
No interchangeable product listed in the Ontario extract
Kenalog-10 · DIN 01999761 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 Health Canada: Marketed since 2009-12-02 · brand KENALOG-10 INJECTION · ATC H02AB08 TRIAMCINOLONE · form Suspension · route Intra-articular, Intrasynovial, Intradermal, Intrabursal · ingredients TRIAMCINOLONE ACETONIDE 10 MG/ML · company Bristol-myers squibb canada · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Kenalog-10: Formulary list price $19.45 per unit (the source does not state the unit; exact figure $19.4500). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01999761)

Source record
DIN 01999761: Kenalog-10 Raw flags: sec3=Y Item: 680400035; group id 720; item number 1779; lccId None; manufacturer id BQU Source form: Inj Susp-5mL Pk; strength: 50mg/5mL Recorded listing: General benefit Source prices (unrounded): $19.4500; ministry $19.4500 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01999761 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15482
Shortage status: active shortage (reported June 13, 2025, estimated to end December 31, 2026, last updated August 14, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01999761
Shortage record checked October 6, 2026

Kenalog-40 · DIN 01999869 · 200 mg/5 mL · injection suspension-5mL Pk

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
No interchangeable product listed in the Ontario extract
Kenalog-40 · DIN 01999869 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 Health Canada: Marketed since 2010-11-23 · brand KENALOG-40 INJECTION · ATC H02AB08 TRIAMCINOLONE · form Suspension · route Intra-articular, Intramuscular · ingredients TRIAMCINOLONE ACETONIDE 40 MG/ML · company Bristol-myers squibb canada · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Kenalog-40: Formulary list price $31.65 per unit (the source does not state the unit; exact figure $31.6500). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01999869)

Source record
DIN 01999869: Kenalog-40 Raw flags: sec3=Y Item: 680400034; group id 720; item number 1780; lccId None; manufacturer id BQU Source form: Inj Susp-5mL Pk; strength: 200mg/5mL Recorded listing: General benefit Source prices (unrounded): $31.6500; ministry $31.6500 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01999869 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15481
Shortage status: active shortage (reported April 16, 2025, estimated to end December 31, 2026, last updated August 14, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01999869
Shortage record checked October 6, 2026

Aristocort R · DIN 02194058 · 0.1% · Cr

Listed, not a benefitMarketed · checked October 5, 2026
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Aristocort R · DIN 02194058 Manufacturer: Valeant Canada Ltd.; listing date 1998-03-17 Health Canada: Marketed since 2020-11-24 · brand ARISTOCORT R · ATC D07AB09 TRIAMCINOLONE · form Cream · route Topical · ingredients TRIAMCINOLONE ACETONIDE 0.1 %/W/W · company Bausch health, canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Aristocort R: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02194058)

Source record
DIN 02194058: Aristocort R Raw flags: notABenefit=Y, sec3=Y Item: 840600029; group id 850; item number 2067; lccId None; manufacturer id VAL Source form: Cr; strength: 0.1% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02194058 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=35784
Interchangeable products
Kenalog · DIN 00029114 · not recorded Triaderm · DIN 00716960 · $0.0533
Shortage status: resolved shortage (ended December 1, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02194058
Shortage record checked October 6, 2026

Apo-Triamcinolone AQ · DIN 02437635 · 55 mcg/Metered Dose · Nas Sp-120 Dose Pk (with Preservative)

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Apo-Triamcinolone AQ · DIN 02437635 Manufacturer: Apotex Inc.; listing date 2016-08-30 Health Canada: Marketed since 2016-06-15 · brand APO-TRIAMCINOLONE AQ · ATC R01AD11 TRIAMCINOLONE · form Spray (metered-dose) · route Nasal · ingredients TRIAMCINOLONE ACETONIDE 55 MCG/ACT · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Triamcinolone AQ: Formulary list price $18.00 per unit (the source does not state the unit; exact figure $18.0000). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02437635)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02437635). DIN 02437635: Apo-Triamcinolone AQ Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 520800036; group id 601; item number 1561; lccId None; manufacturer id APX Source form: Nas Sp-120 Dose Pk (with Preservative); strength: 55mcg/Metered Dose Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $18.0000; ministry $18.0000 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02437635 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92202
Interchangeable products
Nasacort AQ · DIN 02213834 · not recorded
Shortage status: active shortage (reported June 2, 2026, estimated to end November 20, 2026, last updated October 2, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02437635
Shortage record checked October 6, 2026

Nasacort AQ · DIN 02213834 · 55 mcg/Metered Dose · Nas Sp-120 Dose Pk (with Preservative)

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Nasacort AQ · DIN 02213834 Manufacturer: Sanofi Consumer Health Inc.; listing date 2016-08-30 Health Canada: Marketed since 2022-07-16 · brand NASACORT AQ · ATC R01AD11 TRIAMCINOLONE · form Spray (metered-dose) · route Nasal · ingredients TRIAMCINOLONE ACETONIDE 55 MCG/ACT · company Sanofi consumer health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Nasacort AQ: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02213834)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02213834). DIN 02213834: Nasacort AQ Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 520800036; group id 601; item number 1561; lccId None; manufacturer id SCO Source form: Nas Sp-120 Dose Pk (with Preservative); strength: 55mcg/Metered Dose Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02213834 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19807
Interchangeable products
Apo-Triamcinolone AQ · DIN 02437635 · $18.0000
Shortage status: resolved shortage (ended July 15, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02213834
Shortage record checked October 6, 2026

Kenalog-40 · PIN 00990876 · 40 mg/mL · injection suspension-1mL Pk

General benefitOntario PIN; no Health Canada record under this code
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 01999869 (Marketed, 2010-11-23) Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15481

Check Health Canada brand DIN
No interchangeable product listed in the Ontario extract
Kenalog-40 · DIN 00990876 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 01999869 (Marketed, 2010-11-23) Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15481
Re-check Health Canada status and shortages (live)

Kenalog-40: Formulary list price $8.96 per unit (the source does not state the unit; exact figure $8.9610). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 00990876)

Source record
DIN 00990876: Kenalog-40 Raw flags: sec3=Y Item: 680400036; group id 720; item number 1778; lccId None; manufacturer id BQU Source form: Inj Susp-1mL Pk; strength: 40mg/mL Recorded listing: General benefit Source prices (unrounded): $8.9610; ministry $8.9610 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00990876 Health Canada record for this brand: DIN 01999869 (Marketed, November 23, 2010) Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15481
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00990876
Shortage record checked October 6, 2026

Kenalog · PIN 00029114 · 0.1% · Cr

Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot paid by ODB 65 and over; see alternatives

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
1 brand, same coverage
Kenalog · DIN 00029114 Manufacturer: Westwood Squibb Pharmaceuticals; listing date 1996-10-01 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Re-check Health Canada status and shortages (live)

Kenalog: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 00029114)

Source record
DIN 00029114: Kenalog Raw flags: notABenefit=Y, sec3=Y Item: 840600029; group id 850; item number 2067; lccId None; manufacturer id WSQ Source form: Cr; strength: 0.1% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00029114 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Aristocort R · DIN 02194058 · not recorded Triaderm · DIN 00716960 · $0.0533
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00029114
Shortage record checked October 6, 2026

Kenalog · DIN 01999796 · 0.1% · Oint

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2004-08-05 — choose a marketed DIN from the same-category list.Discontinued August 5, 2004 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2004-08-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2004-08-05 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Kenalog · DIN 01999796 Manufacturer: Westwood Squibb Pharmaceuticals; listing date 1996-10-01 Health Canada: Cancelled post market since 2004-08-05 · brand KENALOG OINTMENT 0.1% · ATC D07AB09 TRIAMCINOLONE · form Ointment · route Topical · ingredients TRIAMCINOLONE ACETONIDE 1 MG/G · company Westwood-squibb, division of bristol-myers squibb canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Kenalog: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01999796)

Source record
DIN 01999796: Kenalog Raw flags: notABenefit=Y, sec3=Y Item: 840600030; group id 850; item number 2068; lccId None; manufacturer id WSQ Source form: Oint; strength: 0.1% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01999796 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19868
Interchangeable products
Aristocort R · DIN 02194031 · $0.1856
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01999796
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 5, 2004 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (D07AB, H02AB, R01AD): coverage varies; not interchangeable

  • Beclomethasone dipropionate (Mylan-Beclo AQ): general benefit, not a benefit
  • Budesonide (Rhinocort Aqua): general benefit, not a benefit
  • Ciclesonide (Alvesco): general benefit
  • Desonide (Tridesilon): general benefit, not a benefit
  • Dexamethasone (Decadron): general benefit, not a benefit
  • Dexamethasone (Decadron): general benefit, not a benefit

20 more in the class list below

Triamcinolone acetonide 0.1% in orabase

1 general benefit · 1 not a benefit

Oracort · DIN 01964054 · · Oral Top Oint

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Oracort · DIN 01964054 Manufacturer: Taro Pharmaceuticals Inc.; listing date 1996-10-01 Health Canada: Marketed since 2021-10-12 · brand ORACORT · ATC A01AC01 TRIAMCINOLONE · form Paste · route Dental · ingredients TRIAMCINOLONE ACETONIDE 0.1 % · company Taropharma, a division of taro pharmaceuticals inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Oracort: Formulary list price $1.56 per unit (the source does not state the unit; exact figure $1.5607). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01964054)

Source record
DIN 01964054: Oracort Raw flags: sec3=Y Item: 840600034; group id 851; item number 2069; lccId None; manufacturer id TAR Source form: Oral Top Oint; strength: None Recorded listing: General benefit Source prices (unrounded): $1.5607; ministry $1.5607 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01964054 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13360
Interchangeable products
Kenalog-Orabase · DIN 01999788 · not recorded
Shortage status: resolved shortage (ended April 3, 2020); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01964054
Shortage record checked October 6, 2026

Kenalog-Orabase · DIN 01999788 · · Oral Top Oint

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-09-04 — choose a marketed DIN from the same-category list.Discontinued September 4, 2008 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-09-04 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2008-09-04 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Kenalog-Orabase · DIN 01999788 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 Health Canada: Cancelled post market since 2008-09-04 · brand KENALOG IN ORABASE 0.1% · ATC A01AC01 TRIAMCINOLONE · form Paste · route Dental · ingredients TRIAMCINOLONE ACETONIDE 1 MG/G · company Bristol-myers squibb canada · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Kenalog-Orabase: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01999788)

Source record
DIN 01999788: Kenalog-Orabase Raw flags: notABenefit=Y, sec3=Y Item: 840600034; group id 851; item number 2069; lccId None; manufacturer id BQU Source form: Oral Top Oint; strength: None Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01999788 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14583
Interchangeable products
Oracort · DIN 01964054 · $1.5607
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01999788
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since September 4, 2008 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (D07AB, H02AB, R01AD): coverage varies; not interchangeable

  • Beclomethasone dipropionate (Mylan-Beclo AQ): general benefit, not a benefit
  • Budesonide (Rhinocort Aqua): general benefit, not a benefit
  • Ciclesonide (Alvesco): general benefit
  • Desonide (Tridesilon): general benefit, not a benefit
  • Dexamethasone (Decadron): general benefit, not a benefit
  • Dexamethasone (Decadron): general benefit, not a benefit

20 more in the class list below

Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (52:08 Anti-Inflammatory Agents) and how they are covered

Matched class: 52:08 Anti-Inflammatory Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: DEXAMETHASONE, FLUMETHASONE PIVALATE & IODOCHLORHYDROXYQUIN, FLUOROMETHOLONE, FLUOROMETHOLONE ACETATE, KETOROLAC TROMETHAMINE, LODOXAMIDE TROMETHAMINE Some products covered without a code (check the product listing): BECLOMETHASONE DIPROPIONATE, BUDESONIDE, PREDNISOLONE ACETATE 52:08 Anti-Inflammatory Agents

BECLOMETHASONE DIPROPIONATE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 50mcg · Nas-Sp-200 Dose Pk

BUDESONIDE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 64mcg/Metered Dose, 100mcg/Metered Dose · Nas Sp-120 Dose Pk, Nas Sp-165 Dose Pk

AZELASTINE HCL & FLUTICASONE PROPIONATE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 137mcg/Actuation&50mcg/Actuation · Nas-Sp-120 Dose Pk

FLUTICASONE PROPIONATE

· 4 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mcg/Actuation · Nas Sp-120 Dose Pk

MOMETASONE FUROATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mcg/Dose · Nas Sp-140 Dose Pk

DEXAMETHASONE

· 2 products · General benefit · strengths: 0.1% · Oph Oint-3.5g Pk, Oph Susp

FLUMETHASONE PIVALATE & IODOCHLORHYDROXYQUIN

· 1 products · General benefit · strengths: 0.02% & 1% · Ot Sol

FLUOROMETHOLONE

· 1 products · General benefit · strengths: 0.1% · Oph Susp

FLUOROMETHOLONE ACETATE

· 1 products · General benefit · strengths: 0.1% · Oph Susp

KETOROLAC TROMETHAMINE

· 3 products · General benefit · strengths: 0.5%, 0.45% w/v · Oph Sol, Oph Sol-0.4mL Vial Pk (Preservative-Free)

LODOXAMIDE TROMETHAMINE

· 1 products · General benefit · strengths: 0.1% · Oph Sol

PREDNISOLONE ACETATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 1% · Oph Susp Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 52:08 and 2 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors, 52:36 Other Eye, Ear, Nose and Throat Agents

Other drugs in the same formulary class (68:04 Corticosteroids) and how they are covered

Matched class: 68:04 Corticosteroids

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, CICLESONIDE, FLUDROCORTISONE ACETATE, FLUTICASONE FUROATE, FLUTICASONE PROPIONATE, METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, MOMETASONE FUROATE Some products covered without a code (check the product listing): BUDESONIDE, DEXAMETHASONE, DEXAMETHASONE 21-PHOSPHATE, HYDROCORTISONE, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE 68:04 Corticosteroids

CICLESONIDE

· 3 products · General benefit · strengths: 100mcg/Actuation, 200mcg/Actuation, 50mcg/Actuation · Inh-120 Dose Pk, Metered Dose Nas Sp-120 Dose Pk

DEXAMETHASONE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 0.5mg, 4mg · Tab

DEXAMETHASONE 21-PHOSPHATE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 4mg/mL · Inj Sol

HYDROCORTISONE

· 5 products · General benefit (4), Temporary benefit (1) · strengths: 10mg, 20mg · Tab

METHYLPREDNISOLONE

· 1 products · General benefit · strengths: 4mg · Tab

METHYLPREDNISOLONE ACETATE

· 3 products · General benefit · strengths: 40mg/mL, 80mg/mL, 100mg/5mL · Inj Susp-1mL Pk, Inj Susp-5mL Pk

PREDNISOLONE SODIUM PHOSPHATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 6.7mg/5mL · O/L

PREDNISONE

· 7 products · General benefit (5), Listed, not a benefit (2) · strengths: 1mg, 5mg, 50mg · Tab

TRIAMCINOLONE HEXACETONIDE

· 1 products · Limited Use, codes 580 · strengths: 20mg/mL · 1mL-Amp Pk

FLUDROCORTISONE ACETATE

· 2 products · General benefit · strengths: 0.1mg · Tab

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 50mcg/Metered Dose, 100mcg/Metered Dose · Aero Inh-200 Dose Pk

BUDESONIDE

· 12 products · Limited Use, codes 260, 261, 262, 263, 264 (9), General benefit (3) · strengths: 0.125mg/mL, 0.25mg/mL, 0.5mg/mL, 100mcg/Metered Dose, 200mcg/Metered Dose, 400mcg/Metered Dose · Inh Susp, Pd Inh-200 Dose Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 68:04 and 5 more
Full class listing Related classes: 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids

Other drugs in the same formulary class (84:06 Anti-Inflammatory) and how they are covered

Matched class: 84:06 Anti-Inflammatory

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL, BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE, CALCIPOTRIOL & BETAMETHASONE DIPROPIONATE, HALOBETASOL PROPIONATE, MOMETASONE FUROATE Some products covered without a code (check the product listing): AMCINONIDE, BETAMETHASONE DIPROPIONATE, BETAMETHASONE VALERATE, CLOBETASOL PROPIONATE, DESONIDE, FLUOCINONIDE, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE VALERATE 84:06 Anti-Inflammatory

DESONIDE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.05% · Cr, Oint

AMCINONIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 0.1% · Cr

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 0.025% · Cr, Oint

BETAMETHASONE DIPROPIONATE

· 6 products · General benefit (5), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 0.05% · Cr, Lot, Oint

BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL

· 2 products · General benefit · strengths: 0.05% · Oint

BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE

· 2 products · General benefit · strengths: 0.05% · Cr

BETAMETHASONE VALERATE

· 19 products · Listed, not a benefit (7), General benefit (12) · strengths: 0.05%, 0.1% · Cr, Lot, Oint, Scalp Lot

CLOBETASOL PROPIONATE

· 20 products · General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 0.05%, 0.05% w/w · Cr, Oint, Scalp Lot, Top Shampoo, Top Sol Sp

FLUOCINONIDE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 0.05% · Cr, Emol Cr, Gel, Oint

HALOBETASOL PROPIONATE

· 1 products · General benefit · strengths: 0.01% w/w · Lot

HYDROCORTISONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.5%, 1% · Oint

HYDROCORTISONE ACETATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 1% · Cr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:06 and 4 more
Full class listing Related classes: 84:04 Anti-Infectives, 84:28 Keratolytic Agents, 84:36 Miscellaneous Skin and Mucous Membrane Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no link
What the Health Canada label says it is for
Product monograph unavailable: no link

Availability

Kenalog-10 · DIN 01999761 Shortage status: active shortage (reported 2025-06-13, estimated to end 2026-12-31, last updated 2026-08-14); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01999761

Check this DIN again

Kenalog-40 · DIN 01999869 Shortage status: active shortage (reported 2025-04-16, estimated to end 2026-12-31, last updated 2026-08-14); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01999869

Check this DIN again

Apo-Triamcinolone AQ · DIN 02437635 Shortage status: active shortage (reported 2026-06-02, estimated to end 2026-11-20, last updated 2026-10-02); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02437635

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Aristocort R, Apo-Triamcinolone AQ, Nasacort AQ, Kenalog, Kenalog-Orabase: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026